...
首页> 外文期刊>Cell death & disease. >Intravenous immunoglobulin suppresses NLRP1 and NLRP3 inflammasome-mediated neuronal death in ischemic stroke
【24h】

Intravenous immunoglobulin suppresses NLRP1 and NLRP3 inflammasome-mediated neuronal death in ischemic stroke

机译:静脉注射免疫球蛋白抑制缺血性卒中中NLRP1和NLRP3炎性体介导的神经元死亡

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Multi-protein complexes called inflammasomes have recently been identified and shown to contribute to cell death in tissue injury. Intravenous immunoglobulin (IVIg) is an FDA-approved therapeutic modality used for various inflammatory diseases. The objective of this study is to investigate dynamic responses of the NLRP1 and NLRP3 inflammasomes in stroke and to determine whether the NLRP1 and NLRP3 inflammasomes can be targeted with IVIg for therapeutic intervention. Primary cortical neurons were subjected to glucose deprivation (GD), oxygen–glucose deprivation (OGD) or simulated ischemia-reperfusion (I/R). Ischemic stroke was induced in C57BL/6J mice by middle cerebral artery occlusion, followed by reperfusion. Neurological assessment was performed, brain tissue damage was quantified, and NLRP1 and NLRP3 inflammasome protein levels were evaluated. NLRP1 and NLRP3 inflammasome components were also analyzed in postmortem brain tissue samples from stroke patients. Ischemia-like conditions increased the levels of NLRP1 and NLRP3 inflammasome proteins, and IL-1 β and IL-18, in primary cortical neurons. Similarly, levels of NLRP1 and NLRP3 inflammasome proteins, IL-1 β and IL-18 were elevated in ipsilateral brain tissues of cerebral I/R mice and stroke patients. Caspase-1 inhibitor treatment protected cultured cortical neurons and brain cells in vivo in experimental stroke models. IVIg treatment protected neurons in experimental stroke models by a mechanism involving suppression of NLRP1 and NLRP3 inflammasome activity. Our findings provide evidence that the NLRP1 and NLRP3 inflammasomes have a major role in neuronal cell death and behavioral deficits in stroke. We also identified NLRP1 and NLRP3 inflammasome inhibition as a novel mechanism by which IVIg can protect brain cells against ischemic damage, suggesting a potential clinical benefit of therapeutic interventions that target inflammasome assembly and activity.
机译:最近发现了被称为炎症小体的多蛋白复合物,这些复合物可导致组织损伤中的细胞死亡。静脉免疫球蛋白(IVIg)是FDA批准的用于多种炎症性疾病的治疗方式。这项研究的目的是调查中风中NLRP1和NLRP3炎性小体的动态反应,并确定IVIg是否可以靶向NLRP1和NLRP3炎性小体进行治疗干预。对原代皮层神经元进行葡萄糖剥夺(GD),氧葡萄糖剥夺(OGD)或模拟的缺血再灌注(I / R)。通过大脑中动脉闭塞,然后再灌注,在C57BL / 6J小鼠中诱发缺血性中风。进行了神经学评估,量化了脑组织损伤,并评估了NLRP1和NLRP3炎性小体蛋白水平。还对中风患者的死后脑组织样本中的NLRP1和NLRP3炎性体成分进行了分析。缺血样疾病增加了原代皮层神经元中NLRP1和NLRP3炎性小体蛋白以及IL-1β和IL-18的水平。同样,在脑I / R小鼠和中风患者的同侧脑组织中,NLRP1和NLRP3炎性小体蛋白,IL-1β和IL-18的水平升高。 Caspase-1抑制剂治疗可在实验性卒中模型中保护体内培养的皮质神经元和脑细胞。 IVIg处理通过抑制NLRP1和NLRP3炎症小体活性的机制保护了实验性中风模型中的神经元。我们的发现提供了证据,即NLRP1和NLRP3炎性小体在中风的神经元细胞死亡和行为缺陷中起主要作用。我们还确定了NLRP1和NLRP3炎性体抑制是一种新的机制,通过该机制,IVIg可以保护脑细胞免受缺血性损害,这表明针对炎性体组装和活性的治疗干预措施具有潜在的临床益处。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号